KEYNOTE-240 Outcomes Presented at ASCO 2019

KEYNOTE-240  Outcomes Presented at ASCO 2019
Don Photo

Don
3 años 129 Visitas
Categoría:
Descripción:
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center discusses the outcomes of KEYNOTE-240 which compares pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC).